BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:GFH276 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of GFH276\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07198321-2492@assetmemo.bio
DTSTAMP:20261121T004056Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:GFH276: Phase 1/2 readout est. (NCT07198321)
DESCRIPTION:GFH276\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Sing
 le-Arm\, Open-Label\, Multicenter Phase I/II Clinical Study of GFH276 in P
 atients With RAS-Mutant Advanced Solid Tumors\nEstimated primary completio
 n: 30 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gfh2
 76#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7198321
URL:https://assetmemo.bio/drug/gfh276#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07678593-2492@assetmemo.bio
DTSTAMP:20261121T004056Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:GFH276: Phase 1/2 readout est. (NCT07678593)
DESCRIPTION:GFH276\, phase 1/2.\nStudy: A Study of GFH276 Combined With Cet
 uximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Du
 ctal Adenocarcinoma (PDAC) Harboring RAS Mutation\nEstimated primary compl
 etion: November 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /gfh276#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07678593
URL:https://assetmemo.bio/drug/gfh276#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07846358-2492@assetmemo.bio
DTSTAMP:20261121T004056Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:GFH276: Phase 1/2 readout est. (NCT07846358)
DESCRIPTION:GFH276\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: This i
 s a Multicenter\, Open-label\, Phase I/II Study to Explore the Safety\, To
 lerability\, Pharmacokinetics (PK)\, and Preliminary Efficacy of GFH276 in
  Patients With Advanced NSCLC Harboring a RAS Mutation.\nEstimated primary
  completion: December 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/gfh276#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07846358
URL:https://assetmemo.bio/drug/gfh276#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07915921-2492@assetmemo.bio
DTSTAMP:20261121T004056Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:GFH276: Phase 1/2 readout est. (NCT07915921)
DESCRIPTION:GFH276\, phase 1/2.\nStudy: A Phase Ib/II Study of GFH276 in Co
 mbination With Chemotherapy (± Bevacizumab) or Cetuximab in Patients With
  RAS-mutant Metastatic Colorectal Cancer\nEstimated primary completion: 30
  April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gfh276#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07915
 921
URL:https://assetmemo.bio/drug/gfh276#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07784374-2492@assetmemo.bio
DTSTAMP:20261121T004056Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:GFH276: Phase 2 readout est. (NCT07784374)
DESCRIPTION:GFH276\, phase 2.\nStudy: A Phase II Study of GFH375 Combined W
 ith GFS202A or GFH276 Versus GFH375 in Patients With Previously Treated Lo
 cally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS
  G12D Mutation\nEstimated primary completion: 31 August 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/gfh276#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07784374
URL:https://assetmemo.bio/drug/gfh276#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
